Author Archives: Bruno Quinney

Woman with a nose bleed
#Amgen #AstraZeneca #European Union

Tezspire approved in EU for ‘challenging’ rhinosinusitis  

AstraZeneca and Amgen’s Tezspire (tezepelumab) has been approved in the European Union for chronic rhinosinusitis with nasal polyps.  Tezspire has been approved as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) who have not adequately responded to standard… Read More

#News #Regulatory

#antibiotic #Clinical trial #Financing

smartbax raises €4.7 million to advance antibiotic compound 

Biotechnology company smartbax has announced it has raised €4.7 million to advance a novel antibiotic compound through preclinical stage.  The pre-Series A financing round was led by new investors Anobis Asset and Bayern Kapital, with participation from UnternehmerTUM Funding for Innovators as well as existing investors.  The financing will support… Read More

#Business & Investment #News

#Data #Medidata #Sanofi

Sanofi extends Medidata partnership to develop new therapies 

Sanofi has announced it will extend its partnership with technology company Medidata to expedite the development of new therapies.  The new agreement will take advantage of the Medidata Patient, Data, and Study Experiences, building on both organisations’ aim to boost innovation in studies, speed new therapies to market, and promote health… Read More

#Business & Investment #News

#Neuroscience #NRG Therapeutics

NRG Therapeutics announces senior appointments

Neuroscience company NRG Therapeutics has announced an expansion to its senior team as it advances its neurodegenerative disease treatment NRG5051.  Sarah Almond has been appointed as VP of Translational Biology, David Brocklebank as Director of Clinical Operations, and Kathryn Oliver as Director of Project Management. … Read More

#News

#Artificial intelligence (AI) #AstraZeneca #Business #Cell therapy #DDW Turning Science into Business Symposium #Google #Immunotherapy

This week in Drug Discovery (20 – 24 October)

News round-up for 20 – 24 October by Bruno Quinney, Content Team at DDW.  This week’s leading story comes from biotech, with Galapagos announcing plans to shelve its cell therapy business and hundreds of employees set to lose theirjobs. Elsewhere, pharma firms are offering discounts to US… Read More

#News

Pancreatic cancer
#iOnctura #Oncology #Pancreatic cancer #Phase I trial

mPDAC treatment reaches primary endpoint in Phase Ib trial

Cambritaxestat, a treatment for metastatic pancreatic ductal adenocarcinoma (mPDAC), has met its primary endpoint in a Phase Ib trial. Cambritaxestat, an oral autotaxin (ATX) inhibitor, was evaluated in patients with previously untreated mPDAC. The treatment demonstrated safety, tolerability and anti-tumour responses, with data presented at the European Society… Read More

#Cancer Research #News

Enzymes
#Artificial intelligence (AI) #Enzymes #Genomics

IDT and Profluent Bio partner on AI-driven next-gen enzymes

Genomics company Integrated DNA Technologies (IDT) has announced a strategic partnership with AI-first protein design Profluent Bio to design and optimise next-generation enzymes.  The collaboration will bring together Profluent’s generative AI platform with IDT’s expertise in enzymology and genomics, with the aim of exploring new paths for developing novel enzyme… Read More

#Business & Investment #News

Neural networks
#Artificial intelligence (AI) #Flagship Pioneering #Small molecules

Flagship Pioneering unveils $50 million AI platform

Biotechnology company Flagship Pioneering has unveiled its generative AI platform Expedition Medicines, backed by $50 million in funding.  Flagship believes Expedition Medicines will push the boundaries in medicine to enable the creation of first-in-class therapies across oncology, immunology and other diseases. The platform can learn the rules of molecular reactivity… Read More

#Business & Investment #News

Multiple myeloma
#Clinical trial #FDA #Myeloma

FDA grants Fast Track Designation to myeloma treatment HDP-101

The US Food and Drug Administration has granted Fast Track Designation to myeloma candidate HDP-101 from Heidelberg Pharma.  The designation was supported by nonclinical data as well as clinical data from the ongoing Phase I/IIa study with HDP-101, evaluating the safety and antitumour activity of the candidate in patients with… Read More

#News #Regulatory

#Breast cancer #Cancer research #Eli Lilly

Abemaciclib results offer hope for breast cancer treatment

Pharmaceutical company Eli Lilly has announced encouraging results from the Phase III trial of its Verzenio (abemaciclib) treatment for breast cancer.   The data shows that two years of adjuvant abemaciclib plus endocrine therapy (ET) reduced the risk of death from breast cancer by 15.8% versus… Read More

#News

Map of China
#Artificial intelligence (AI) #China #Metabolic diseases #Oncology

Is China the next global biopharma powerhouse?

Regulatory reform and investment in innovation have supercharged China’s biopharma sector, but will ongoing trade wars with the US pose a risk to growth? By Diana Turner. China’s role in the global biopharma sector has grown significantly in recent years. It is the world's largest supplier of active pharmaceutical ingredients (APIs) and in… Read More

#Exclusive Content #Market Reports

#FDA #US government

Trump praises infertility product awarded FDA ‘voucher’

US President Donald Trump has welcomed the US Food and Drug Administration (FDA) awarding a ‘voucher’ to infertility product Pergoveris as part of an unprecedented new scheme.  Pergoveris was one of nine recipients of FDA vouchers handed out under the new Commissioner’s National Priority Voucher (CNPV) pilot… Read More

#News

Leukaemia
#Acute Myeloid Leukaemia #Biotech #European Medicines Agency

Ipsen acquires ImCheck Therapeutics for AML treatment

Pharmaceutical company Ipsen is set to purchase French biotechnology company ImCheck Therapeutics to develop acute myeloid leukaemia (AML) treatment ICT01.  ICT01 is a first-in-class monoclonal antibody targeting BTN3A, a key immune-regulatory molecule broadly expressed across cancer, which received Orphan Drug Designations from the US Food and Drug Administration and European… Read More

#Business & Investment #News

Handshake jigsaw puzzle
#Cancer research #Innovent #Takeda

Takeda and Innovent Biologics partner to develop tumour medicines

Pharmaceutical company Takeda has announced it has entered a global strategic partnership with biotechnology company Innovent Biologics to develop next-generation medicines for cancer tumours.  The agreement will see the development, manufacturing and commercialisation of two late-stage oncology medicines, IBI363 and IBI343, worldwide outside of Greater China. IBI63 is being evaluated… Read More

#Business & Investment #News

The tumour microenvironment
#Biotech #Cancer research #Tumours

Iksuda Therapeutics reveals positive data from IKS014 trial

Biotechnology company Iksuda Therapeutics has announced positive data from the Phase I study of IKS014 for the treatment of cancer patients with advanced HER2+ solid tumours.  IKS014, a human epidermal growth factor receptor 2 (HER2)-directed ADC, resulted in anti-tumour activity across all dose levels in various tumour… Read More

#News

Osteoarthritis
#Arthritis #Biotech #Clinical trial

Elevara Medicines raises $70 million for RA Phase II trial

Biotechnology company Elevara Medicines has raised $70 million in Series A financing to advance its Phase II rheumatoid arthritis (RA) trial and pipeline.  The Series A proceeds, co-led by Forbion and Sofinnova Partners, will support Elevara’s upcoming Phase II clinical trial of its lead candidate ELV001. The investment will also… Read More

#Business & Investment #News